Vaccines
Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.
The U.S. appears to be beating back COVID-19 but it’s still raging in many parts of the world, and studies and trials are still ongoing. Here’s a look at some of today’s top COVID-19 stories.
The vaccine candidate ASP3772 generated an antibody response to each of the 24 polysaccharides in its makeup and antibody response to the two conserved pneumococcal proteins.
The data may show the need for one, but vaccine and immunologists are pushing back against Pfizer and BioNTech’s contention that one is necessary now.
Approximately 100 preliminary reports of GBS have been identified out of 12.8 million doses of the J&J vaccine in the U.S., according to the Centers for Disease Control and Prevention.
The neoantigens market was valued at US$ 2,71,428.57 thousand in 2023, and it is projected to reach US$ 10,54,783.54 thousand by 2028; it is expected to grow at a CAGR of 31.2% from 2023 to 2028.
The Viral Antigens market was valued at US$101.41 million in 2019 and is projected to reach US$ 236.80 million by 2027; it is expected to grow at a CAGR of 11.0% during 2020–2027.
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
A Phase II study shows the vaccine by Imugene Limited improved survival rates and overall response in patients with HER2-positive stomach or gastroesophageal junction cancer.
The vaccine demonstrated efficacy in mild, moderate, and severe COVID-19 of 77.8% with efficacy against severe disease of 93.4%.
PRESS RELEASES